Results 31 to 40 of about 4,906,436 (344)

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Pharmaceutical Research, 2020
The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.
E. Weisberg, A. Parent, Priscilla L. Yang, M. Sattler, Qingsong Liu, Qingwang Liu, Jinhua Wang, Chengcheng Meng, S. Buhrlage, N. Gray, J. Griffin   +10 more
semanticscholar   +1 more source

Biosensors for Screening Kinase Inhibitors [PDF]

Current Topics in Medicinal Chemistry, 2017
For successful drug discovery it is important to understand the fundamentals of the underlying causes and consequences of the diseases for which the drug is being developed. One such physiological process in eukaryotic cells is protein phosphorylation, which is the main post-translational modification of proteins responsible for the onset or ...
Bhalla, Nikhil, Estrela, Pedro
openaire   +2 more sources

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]

, 2017
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.
Aplin, Andrew E., Cheng, Hanyin, Chua, Vivian, Davies, Michael A., Kageyama, Ken, Liao, Connie, Purwin, Timothy J., Sato, Takami, Terai, Mizue   +8 more
core   +2 more sources

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]

, 2019
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner, AB D’Assoro, AJ Lee, AN Hata, Andrei Goga, Andrew D. Simmons, Angel Ku, AS Nikonova, Ashley Maynard, B Melichar, CA Eberlein, CK Lee, CM Blakely, CM Blakely, Collin M. Blakely, D Ercan, DB Costa, F Varghese, Frank McCormick, Golzar Hemmati, Gregor Krings, Hayley J. Donnella, Henry J. Haringsma, J Chen, J Fu, Jacqueline Galeas, JJ Chabon, Jonathan Kuhn, Julia Rohrberg, Julia Rotow, K Shien, Khyati N. Shah, KS Thress, L Li, Liliane Robillard, LV Sequist, LV Sequist, M Moustafa-Kamal, M Ramirez, Maria M. Martins, MJ Niederst, MS Cragg, MW Karaman, OJ Gruss, PA Jänne, R Rosell, RA Burrell, Roma Bhatt, S Anand, S Stewart, Sophie Dumont, Sourav Bandyopadhyay, SV Sharma, Swati Kaushik, T Sharifnia, TC Chou, TG Bivona, TG Bivona, Thomas C. Harding, TM Kim, Trever G. Bivona, V Bavetsias, Victor Olivas, Victoria E. Wang, Y Zhou, Z Piotrowska, Z Yang   +66 more
core   +1 more source

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs

Frontiers in Chemistry, 2020
Rational drug design implies usage of molecular modeling techniques such as pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking to explain the activity of biomolecules, define molecular determinants for interaction with ...
Ž. Gagić, Dušan Ružić, N. Djoković, Teodora Djikić, K. Nikolić   +4 more
semanticscholar   +1 more source

Special Issue: Kinase inhibitors

Molecules, 2018
n ...
Pierre Koch, Stefan Laufer
doaj   +1 more source

Rho-kinase inhibitors

Folia Pharmacologica Japonica, 2011
Rhoキナーゼは1995～1996年に，低分子量GTP結合タンパク質Rhoの標的タンパク質として同定されたセリン・スレオニンタンパク質リン酸化酵素である．これまでの研究により，Rhoキナーゼは収縮，増殖，遊走，遺伝子発現誘導など細胞の重要な生理機能に関与していることが明らかになっている．また各種病態動物モデルを使用した解析より，Rhoキナーゼの活性亢進が数々の病態を引き起こす原因となっていることが示され，創薬のターゲットとして注目されている．RhoキナーゼにはROCK1とROCK2の2つのアイソフォームがあり高い相同性を有している．ROCK1とROCK2は体内に広く発現しているがROCK2は特に脳と骨格筋に強く発現している．現在製薬メーカーを中心に精力的にRhoキナーゼ阻害薬の開発が行われている ...
Minoru, Seto, Toshio, Asano
openaire   +3 more sources

Intracellular mechanisms underlying the nicotinic enhancement of LTP in the rat dentate gyrus [PDF]

, 2008
We have previously shown that activation of nicotinic acetylcholine receptors (nAChRs) enhanced long-term potentiation (LTP) in the rat dentate gyrus in vitro via activation of α7 nAChR. In the present studies, mechanisms underlying the acute and chronic
Abel, Arendt, Atack, Bain, Bear, Blanquet, Bliss, Blitzer, Blitzer, Bogan, Casey, Charpantier, Cho, Dajas-Bailador, Davies, Davis, Decker, Dhavan, Dominguez del Toro, English, Faghih, Fujii, Giovannini, Gray, Hope, Huang, Huang, Hunter, Hurst, Ji, Jones, Kawakami, Kelly, Kihara, Klein, Krause, Le Novere, Levin, Li, Liston, Lu, Man, Mann, Marrero, Matsuyama, Matthies, Meriane, Opazo, O’Dell, Peavy, Picciotto, Polesskaya, Polesskaya, Radcliffe, Roberson, Rush, Salazar, Sanna, Sanna, Santos, Seguela, Sharifzadeh, Sharifzadeh, Sharma, Shaw, Shaw, Sweatt, Takada-Takatori, Tominaga-Yoshino, Wada, Wang, Wang, Welsby, Welsby, Whitehouse, Woo, Wu, Yang, Ying, Yu, Zhang, Zwart   +81 more
core   +1 more source

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

, 2020
The signalling pathways initiated by members of the transforming growth factor-β (TGFβ) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFβ
A Rojas-Fernandez, A Woods, AR Ramjaun, AY Hsing, B Bierie, B Ozdamar, B-C Kim, BR Binder, C Allan, CJ David, CS Hill, DB Shackelford, EC Connolly, FA Ran, G Avery-Cooper, G Rena, G Rosti, GD Cuny, GJ Inman, GJ Inman, GM Keating, H Ikushima, J Massagué, J Massagué, J Massaous, J Ozanne, J Song, J Vogt, J Xu, JF Callahan, JL Wrana, JM Lizcano, Joan Massagué, JY Altarejos, K Clark, KA Brown, KJ Livak, LC Spender, LC Spender, M Abe, M Kowanetz, M Tojo, MO Li, MR Keeton, NJ Bright, P Lönn, PH Lin, PK Datta, PM Siegel, RJ Akhurst, RJ Akhurst, S DaCosta Byfield, S Dennler, S Edlund, S Strickson, SA Hawley, T Sonntag, TB Sundberg, Y Drabsch, Y Liu, Y Shi, Y Yang, Y Zhang, Y Zhang   +63 more
core   +2 more sources

Protein Kinase Inhibitors

Folia Biologica, 2006
Since protein kinases have been found to be implicated in many diseases, first of all malignancies, they are considered as promising therapeutic targets. Many protein kinase inhibitors have been designed by now. These molecules have a low molecular weight and most of them bind to protein kinases competing with ATP for the ATP-binding site. Some protein
I, Shchemelinin, L, Sefc, E, Necas
openaire   +2 more sources